Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetyldigitoxin is a cardenolide glycoside derived from digitoxin, used primarily as a cardiotonic and anti-arrhythmic agent in the management of congestive heart failure and certain cardiac arrhythmias. It acts by inhibiting the sodium/potassium-transporting ATPase (Na+/K+ ATPase) pump on the membranes of cardiac myocytes. This inhibition increases intracellular sodium, which subsequently raises intracellular calcium via reduced activity of the Na+/Ca2+ exchanger. The increased calcium enhances myocardial contractility (positive inotropic effect). Additionally, acetyldigitoxin increases vagal tone through central nervous system effects, slowing conduction through the atrioventricular node—an important mechanism for controlling ventricular rate in atrial fibrillation or flutter. Acetyldigitoxin is well absorbed orally and has been used for rapid digitalization due to its pharmacokinetic properties[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetyldigitoxin.